- Alzheimer’s disease is the most common form of dementia, and the number of people with the condition is increasing rapidly.
- Treatment is most effective if started in the early stages, so research is focusing on early diagnosis.
- Scientists can detect biomarkers for Alzheimer’s disease in cerebrospinal fluid (CSF), but CSF sampling involves a lumbar puncture that can be distressing and take several days to recover from.
- Now, a study has detected Alzheimer’s disease biomarkers in the blood, potentially leading to easier, earlier tests for Alzheimer’s disease.
Dementia currently affects
Available treatments work to relieve the symptoms, which may include:
- memory loss: problems taking in and remembering information
- cognitive deficits: difficulty with reasoning, complex tasks, and judgment
- problems recognising people or things
- problems with spatial awareness
- difficulty speaking, reading, or writing
- personality or behavior changes.
Alzheimer’s disease is characterized by
Newer disease-modifying treatments, the monoclonal antibodies
These treatments are
However, to sample CSF a clinician must perform a
New research from The Global Alzheimer’s Platform Foundation has suggested that these biomarkers can also be detected in blood samples.
The…
Read the full article here